In addition to the fact that Peru is the most affected by the “Lampada” mutant, it was the first country in which the first infection with the new strain was reported, as it was in August 2020. By April 2021, 97 percent of cases infected with this mutation were in Peru alone, but it is now spreading rapidly in many countries of the world.
Science Alert points out that there are many reasons for Peru’s poor performance in the face of the epidemic, from a poorly funded and ill-equipped health care system with too few intensive care beds; To the slow provision of vaccines, as well as limited testing capacity, with overcrowded housing and population.
On June 14, the World Health Organization declared that “the lambda mutant must be of interest to the world.” The United Kingdom has recorded eight confirmed cases of lambda, most of which have been linked to travel abroad.
Science Alert stresses that the lambada should really be of interest, because it is the type that contains molecules that spread quickly and cause strong symptoms, as well as its ability to evade immunity from infection or combat previous vaccines.
Many scientists talk about an “unusual combination” of mutations in the lambda, which may make it more transmissible, according to the site.
The site explains that the new mutant has seven molecules in the barbed protein, which are protrusions on the outer envelope of the virus that help it adhere to and invade our cells. These molecules make it easier for the lambda mutant to attach to our cells and make it more difficult for our antibodies to attach to and neutralize the virus.
There are no published studies yet on the lambda variant, but a preliminary version of research by New York University’s Grossman School of Medicine on the effect of the Pfizer and Moderna vaccines against the lambda variant revealed that the antibodies induced by the two vaccines against the new strain became two to three times lower than what the two vaccines produced In front of the original virus.
Researchers from the University of Chile also investigated the effect of the Sinovac vaccine against the lambda variant, and also found a threefold reduction in neutralizing antibodies compared to the original mutant.
But according to the recent Public Health England “risk assessment” of the lambda mutant, there is no evidence of a country in which the mutant outperformed delta.